(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 May 2022 (27.05.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/109178 A1

(51) International Patent Classification:
A61K 39/00 (2006.01) *A61K 45/06* (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/US2021/059955

(22) International Filing Date:
18 November 2021 (18.11.2021)

(25) Filing Language: English

(26) Publication Language: English


(30) Priority Data:
63/115,272 18 November 2020 (18.11.2020) US
63/244,662 15 September 2021 (15.09.2021) US

(71) Applicant: **PIONYR IMMUNOTHERAPEUTICS, INC.** [US/US]; 2 Tower Place, Suite 800, South San Francisco, California 94080 (US).

(72) Inventors: **JAHCHAN, Nadine**; c/o PIONYR IMMUNOTHERAPEUTICS, INC., 2 Tower Place, Suite 800, South San Francisco, California 94080 (US). **STREULI, Michel**; c/o PIONYR IMMUNOTHERAPEUTICS, INC., 2 Tower Place, Suite 800, South San Francisco, California 94080 (US). **YANG, Xi**; c/o PIONYR IMMUNOTHERAPEUTICS, INC., 2 Tower Place, Suite 800, South San Francisco, California 94080 (US). **LIANG, Linda**; c/o PIONYR IMMUNOTHERAPEUTICS, INC., 2 Tower Place, Suite 800, South San Francisco, California 94080 (US). **SRIRAM, Venkataraman**; c/o PIONYR IMMUNOTHERAPEUTICS, INC., 2 Tower Place, Suite 800, South San Francisco, California 94080 (US). **POLLACK, Joshua**; c/o PIONYR IMMUNOTHERAPEUTICS, INC., 2 Tower Place, Suite 800, South San Francisco, California 94080 (US). **JURIC, Vladislava**; c/o PIONYR IMMUNOTHERAPEUTICS, INC., 2 Tower Place, Suite 800, South San Francisco, California 94080 (US). **HAEGGBLOM, Linnea**; c/o PIONYR IMMUNOTHERAPEUTICS, INC., 2 Tower Place, Suite 800, South San Francisco, California 94080 (US). **MOJICA, Kara**; c/o PIONYR IMMUNOTHERAPEUTICS, INC., 2 Tower Place, Suite 800, South San Francisco, California 94080 (US). **PRESTA, Leonard, G.**; c/o PIONYR IMMUNOTHERAPEUTICS, INC., 2 Tower Pl, Suite 800, South San Francisco, California 94080 (US). **MITRA, Sayantam**; c/o PIONYR IMMUNOTHERAPEUTICS, INC., 2 Tower Pl, Suite 800, South San Francisco, California 94080 (US).

(54) Title: ANTI-MARCO ANTIBODIES AND USES THEREOF

FIG. 1



(57) Abstract: Provided herein are anti-MARCO antibodies. Provided are also methods of generating and using anti-MARCO antibodies.

[Continued on next page]

WO 2022/109178 A1

(74) **Agent: WIENS, Mayim E.** et al.; Goodwin Procter LLP, 100 Northern Avenue, IP DOCKETING DEPT./7TH FL, Boston, Massachusetts 02210 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*